Eight new medicines have been recommended for approval at the May 2015 meeting of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). 22 May 2015
US biotech firm Eureka Therapeutics and German family-owned pharma major Boehringer Ingelheim announced today that they have entered into a research agreement for the discovery of novel therapeutic antibodies in oncology. 22 May 2015
Eisai has launched its in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) as a treatment for unresectable thyroid cancer in Japan. 21 May 2015
Swiss drug major Novartis announced that the Phase III study of Afinitor (everolimus) tablets plus best supportive care in nonfunctional neuroendocrine tumors of gastrointesinal or lung origin met its primary endpoint. 21 May 2015
Ipsen has signed an agreement to acquire OctreoPharm Sciences, a private German life sciences company focusing on the development of innovative radioactive labeled compounds for molecular imaging diagnostics and therapeutic applications. 20 May 2015
US cancer immunotherapies firm Advaxis has entered into a non-exclusive research and clinical trial collaboration agreement with Sorrento Therapeutics. 19 May 2015
The US Food and Drug Administration has granted Fast Track designations to US biopharma companies Celgene Corp and Acceleron Pharma’s luspatercept for two separate indications. 19 May 2015
German biotech firm BioNTech has signed an agreement with Danish peer Genmab to jointly research, develop and commercialize multiple bispecific antibodies for cancer immunotherapy 19 May 2015
US late-stage clinical oncology firm Sorrento Therapeutics says it has formed a wholly-owned subsidiary, TNK Therapeutics, which will focus on developing CAR.TNKs. 18 May 2015
Japanese drug major Astellas Pharma has released positive new data on two of its drug candidates, mirabegron and enzalutamide, at the 2015 annual meeting of the American Urological Association (AUA). 18 May 2015
US late-stage clinical oncology firm Sorrento Therapeutics says that NantPharma, founded by Patrick Soon-Shiong and a member of the NantWorks ecosystem of companies, agreed to acquire the rights to Cynviloq through the acquisition of its wholly-owned subsidiary Igdrasol. 15 May 2015
Data from a Phase III study has shown that adding elotuzumab, an experimental drug from Bristol-Myers Squibb and AbbVie, to standard therapy, led to significantly longer remissions and cut the risk of death in relapsed or refractory multiple myeloma patients. 15 May 2015
US biotech firm Agenus has released impressive data on continuing survival from a Phase II study of its Prophage vaccine in glioblastoma multiforme (GBM). 14 May 2015
Swiss pharma major Roche has announced positive results from two pivotal studies (NP28673 and NP28761) that showed alectinib, its oral investigational anaplastic lymphoma kinase inhibitor (ALKi), shrank tumors. 14 May 2015
Japan’s largest drugmaker Takeda Pharmaceutical has decided to discontinue the Phase III trial of alisertib (MLN8237) for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). 13 May 2015
US health care product company Baxter International has signed a definitive agreement to acquire the Oncaspar (pegaspargase) product portfolio from Italy-based Sigma-Tau Finanziaria. 13 May 2015
German life sciences firm Merck KGaA says that the US Food and Drug Administration has granted Fast Track designation for the development of evofosfamide in pancreatic cancer. 12 May 2015
Canadian biotech firm DelMar Pharmaceuticals, focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments, is the subject of a positive update note from US equity research firm SeeThruEquity. 12 May 2015
In a fourth cancer agreement in the past year, US Pharma major Eli Lilly has entered into a research collaboration to discover novel cancer immunotherapies with German biotech firm BioNTech. 12 May 2015
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
ABL Bio Corp on Friday revealed that it has entered into a clinical trial collaboration and supply agreement with MSD (the ex-US/Canada trading name of Merck & Co. 7 October 2024